Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morgan Cox

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Health Physics|November 4, 2011
2011 Health Physics Honor Roll. Jim JohnsonMorgan Cox
Radiation Protection Dosimetry|August 30, 2008
Letter to the editorMorgan Cox, Arthur Desrosiers, Chuan-Fu Wu
Southern Medical Journal|October 28, 2010
Elevated body mass index in Texas Head Start children: a result of heredity and economicsVeronica Piziak, Maryann Morgan-Cox, Jack Tubbs, et al.
Health Physics|August 27, 2003
Standards for measuring airborne radioactivityMorgan Cox, Mark D Hoover, Liliane Grivaud, et al.
The Annals of Thoracic Surgery|September 18, 2020
Two Decades Using Stentless Porcine Aortic Root in Right Ventricular Outflow Tract ReconstructionMichael W Kasten, Jeremy L Herrmann, Morgan Cox, et al.
Annals of the Rheumatic Diseases|September 5, 2015
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled studyD A Isenberg, M Petri, K Kalunian, et al.
Rheumatology (Oxford, England)|October 19, 2017
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder indexKenneth C Kalunian, Murray B Urowitz, David Isenberg, et al.
Annals of the Rheumatic Diseases|August 22, 2015
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled studyJ T Merrill, R F van Vollenhoven, J P Buyon, et al.
The British Journal of Dermatology|February 9, 2019
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II studyK Reich, P Rich, C Maari, et al.
Gastroenterology|September 8, 2019
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Health Physics|November 4, 2011
2011 Health Physics Honor Roll. Jim JohnsonMorgan Cox
Radiation Protection Dosimetry|August 30, 2008
Letter to the editorMorgan Cox, Arthur Desrosiers, Chuan-Fu Wu
Southern Medical Journal|October 28, 2010
Elevated body mass index in Texas Head Start children: a result of heredity and economicsVeronica Piziak, Maryann Morgan-Cox, Jack Tubbs, et al.
Health Physics|August 27, 2003
Standards for measuring airborne radioactivityMorgan Cox, Mark D Hoover, Liliane Grivaud, et al.
The Annals of Thoracic Surgery|September 18, 2020
Two Decades Using Stentless Porcine Aortic Root in Right Ventricular Outflow Tract ReconstructionMichael W Kasten, Jeremy L Herrmann, Morgan Cox, et al.
Annals of the Rheumatic Diseases|September 5, 2015
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled studyD A Isenberg, M Petri, K Kalunian, et al.
Rheumatology (Oxford, England)|October 19, 2017
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder indexKenneth C Kalunian, Murray B Urowitz, David Isenberg, et al.
Annals of the Rheumatic Diseases|August 22, 2015
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled studyJ T Merrill, R F van Vollenhoven, J P Buyon, et al.
The British Journal of Dermatology|February 9, 2019
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II studyK Reich, P Rich, C Maari, et al.
Gastroenterology|September 8, 2019
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Pageof 2